During the course of MSC-EV therapy, the patient’s pro-inflammatory cytokine response were reduced (IL-1β, TNF-α and IFN-ɣ) and the clinical symptoms of GVHD improved, including indications of cutaneous and mucosal GVHD, which was stable 4 months following completion of therapy (147). This evidence concerns the gene IFNA1 and graft versus host disease.